BIA webinar: what does the new NSI regime mean for your company?

With the National Security and Investment regime coming into force from January 2022, the Government has now published the sector definition of Synthetic Biology. The BIA hosted a webinar with government officials on how the regime will work and what the sector definition of Synthetic Biology might mean for life sciences companies.

Following the panel discussion, there was an opportunity for questions and answers - watch the session below.

Our speakers:

Mick Cooper

Life Sciences Analyst

Office for Life Sciences

Katherine Kingsbury

Associate

Covington & Burling LLP

Katherine Kingsbury is an associate in the Corporate Practice, resident in the firm’s London office, and a member of the firm’s Foreign Direct Investment Regulation team.

Katherine has experience advising on a broad range of corporate matters, including joint ventures, private M&A, takeovers, other significant transactions for public companies, venture capital, restructurings, and general advisory work. She has over 13 years’ experience in corporate practice, including responsibility for knowledge management and training.

In addition, Katherine has particular interest in UK corporate governance and its application to listed companies, larger private companies, and private equity.

Jacqui Ward

Director of National Security & International

BEIS